文献速递心力衰竭与心肌病

司美格鲁肽在肥胖合并轻度降低或保留射血分数心衰患者中的应用

Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2023-10-08

STEP-HFpEF 试验预设分析,纳入 529 例肥胖合并 HFpEF 患者,按基线 LVEF 分为 45%-49%、50%-59% 和 ≥60% 三组。结果显示司美格鲁肽 2.4 mg 在 52 周时改善 KCCQ-CSS、体重、6 分钟步行距离等终点,且各 LVEF 亚组间疗效相似,耐受性良好。

要点

  • 司美格鲁肽改善肥胖 HFpEF 患者的症状、体力受限和运动功能,各 LVEF 亚组一致。
  • 体重下降和炎症标志物降低在各 LVEF 类别间无显著交互作用。
  • 研究支持对肥胖表型 HFpEF 患者使用司美格鲁肽,无论 LVEF 水平。

核心结论

  • 在肥胖合并 HFpEF 患者中,司美格鲁肽 2.4 mg 在各 LVEF 类别中相似地改善症状、体力受限和运动功能,并降低炎症和体重。

研究设计与样本

  • STEP-HFpEF 试验的预设分析,随机分配 529 例患者(司美格鲁肽 263 例,安慰剂 266 例)。
  • 按基线 LVEF 分为三组:45%-49%(n=85)、50%-59%(n=215)和 ≥60%(n=229)。

主要发现

  • 52 周时 KCCQ-CSS 估计治疗差异:EF 45%-49% 为 5.0 分(95%CI -2.7 至 12.8),EF 50%-59% 为 9.8 分(95%CI 5.0 至 14.6),EF ≥60% 为 7.4 分(95%CI 2.8 至 12.0),P 交互=0.56。
  • 体重估计治疗差异:EF 45%-49% 为 -7.6(95%CI -10.7 至 -4.4),EF 50%-59% 为 -10.6(95%CI -12.6 至 -8.6),EF ≥60% 为 -11.9(95%CI -13.8 至 -9.9),P 交互=0.08。
  • 6 分钟步行距离 P 交互=0.19,分层复合终点 P 交互=0.43,高敏 C 反应蛋白 P 交互=0.26,NT-proBNP P 交互=0.96。
  • 司美格鲁肽在各 LVEF 类别中耐受性良好。

临床怎么用

  • 对于肥胖表型 HFpEF 患者,可考虑使用司美格鲁肽 2.4 mg 改善症状和体重,无需根据 LVEF 分层选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many therapies for heart failure (HF) have shown differential impact across the spectrum of left ventricular ejection fraction (LVEF). OBJECTIVES: In this prespecified analysis, the authors assessed the effects of semaglutide across the baseline LVEF strata in patients with the obesity phenotype of HF with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) trial. METHODS: STEP-HFpEF randomized 529 patients (263 semaglutide; 266 placebo). For this prespecified analysis, patients were categorized into 3 groups based on LVEF: 45% to 49% (n = 85), 50% to 59% (n = 215), and ≥60% (n = 229). RESULTS: At 52 weeks, semaglutide improved the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (estimated treatment difference: EF [ejection fraction] 45%-49%: 5.0 points [95% CI: -2.7 to 12.8 points], EF 50%-59%: 9.8 points [95% CI: 5.0 to 14.6 points], and EF ≥60%: 7.4 points [95% CI: 2.8 to 12.0 points]; P interaction = 0.56) and body weight (EF: 45%-49%: -7.6 [95% CI: -10.7 to -4.4], EF 50%-59%: -10.6 [95% CI: -12.6 to -8.6] and EF ≥60%: -11.9 [95% CI: -13.8 to -9.9]; P interaction = 0.08), to a similar extent across LVEF categories. Likewise, LVEF did not influence the benefit of semaglutide on confirmatory secondary endpoints: 6-minute walk distance (P interaction = 0.19), hierarchal composite endpoint (P interaction = 0.43), and high-sensitivity C-reactive protein (P interaction = 0.26); or exploratory endpoint of N-terminal pro-brain natriuretic peptide (P interaction = 0.96). Semaglutide was well-tolerated across LVEF categories. CONCLUSIONS: In patients with HFpEF and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight to a similar extent across LVEF categories. These data support treatment with semaglutide in patients with the obesity phenotype of HFpEF regardless of LVEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Butler, Abildstrøm, Borlaug, et al. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023. PMID: 37993201. doi:10.1016/j.jacc.2023.09.811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。